NYSE · Biotechnology

DNA (DNA) Stock

$8.07 -0.19% NYSE: DNA Healthcare

Valuation

MetricValue
Price$8.07
Market Cap$527.50M
P/E Ratio-1.30
P/B Ratio0.94
P/S Ratio3.48
EPS (TTM)$-5.64
52-Week High$17.58
52-Week Low$5.37
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-61.49%
ROA-27.95%
ROCE-61.89%
Gross Margin-185.29%
Operating Margin-185.29%
Net Margin-2.15%
Debt/Equity0.93
Current Ratio4.92

Annual Financials (USD)

Metric20212022202320242025
Revenue$314.0M$478.0M$251.0M$227.0M$170.0M
Operating Profit$-1.8B$-2.2B$-864.0M$-560.0M$-315.0M
Net Profit$-1.8B$-2.1B$-893.0M$-547.0M$-313.0M
EPS$-55.53$-50.20$-18.40$-10.54$-5.64
Op Margin-582.6%-462.4%-343.8%-246.5%-185.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.1B$2.5B$1.7B$1.4B$1.1B
Total Liabilities$504.0M$803.0M$568.0M$661.0M$611.0M
Cash$1.6B$1.3B$944.0M$562.0M$167.0M
Borrowings$23.0M$443.0M$239.0M$468.0M$417.0M

Latest News

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery PR Newswire · May 26, 2026 Ginkgo Bioworks Holdings Inc (DNA): What’s the Future of Autonomous Lab? Insider Monkey · May 22, 2026 The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales Forecasts Simply Wall St. · May 13, 2026 How The Ginkgo Bioworks (DNA) Story Is Shifting After The Biosecurity Divestiture And Target Cut Simply Wall St. · May 11, 2026 Ginkgo Bioworks Q1 Earnings Call Highlights MarketBeat · May 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-254.0M$-252.0M$-295.0M$-320.0M$-171.0M
Investing Cash Flow$-130.0M$-120.0M$-121.0M$-125.0M$-248.0M
Financing Cash Flow$1.5B$-3.0M$-1.0M$-1.0M$0
Net Cash Flow$1.2B$-223.0M$-380.0M$-384.0M$-393.0M
Free Cash Flow$-310.0M$-304.0M$-336.0M$-382.0M$-179.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-37.26%
Quick Ratio5.15
Interest Coverage—
Return 1Y-43.92%
Return 3Y-91.30%
Return 5Y-97.72%

Ownership

Insiders Held4.60%
Institutions Held68.68%
Institutions Float Held71.99%
Institutional HolderSharesReport Date
Blackrock Inc.3,642,3472026-03-31
Viking Global Investors, L.P.3,577,1282026-03-31
BAILLIE GIFFORD & CO2,391,6492026-03-31
Erste Asset Management GmbH1,947,7282026-03-31
Vanguard Capital Management LLC1,914,4282026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARVN $8.02 -3.43% -6.94 $517.14M 0.00%
ATXSAstria Therapeutics, Inc. $12.58 +0.00% -7.40 $718.13M 0.00%
AVBP $30.84 -0.55% -8.82 $1.44B 0.00%
IOVA $4.36 +1.04% -12.36 $1.95B 0.00%
MBX $65.93 -0.80% -13.02 $3.14B 0.00%

About DNA

DNA is led by CEO Jason Kelly, employs 834 people, headquartered in US, publicly traded since 2021.

DNA stock trades at $8.07 with a market capitalization of $527.50M. The stock is valued at a price-to-earnings (P/E) ratio of -1.30, price-to-book of 0.94, price-to-sales of 3.48. Over the past 52 weeks the stock has ranged between $5.37 and $17.58, and currently trades 54.1% below its 52-week high.

On profitability, DNA generates a return on equity (ROE) of -61.49%, return on capital employed of -61.89%, an operating margin of -185.29%, a net profit margin of -2.15%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides